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Abstract
Background: Spinal muscular atrophy (SMA) is the most common autosomal recessive disease in children, and
the diagnosis is complicated and difficult, especially at early stage. Early diagnosis of SMA is able to improve the
outcome of SMA patients. In our study, Real-time PCR was developed to measure the gene mutation or deletion
of key genes for SMA and to further analyse genotype-phenotype correlation.
Methods: The multiple real-time PCR for detecting the mutations of survival of motor neuron (SMN), apoptosis
inhibitory protein (NAIP) and general transcription factor IIH, polypeptide 2 gene (GTF2H2) was established and
confirmed by DNA sequencing and multiplex ligation-dependent probe amplification (MLPA). The diagnosis and
prognosis of 141 hospitalized children, 100 normal children and further 2000 cases of dry blood spot (DBS) samples
were analysed by this multiple real-time PCR.
Results: The multiple real-time PCR was established and the accuracy of it to detect the mutations of SMN, NAIP
and GTF2H2 was at least 98.8 % comparing with DNA sequencing and MLPA. Among 141 limb movement disorders
children, 75 cases were SMA. 71 cases of SMA (94.67 %) were with SMN c.840 mutation, 9 cases (12 %) with NAIP
deletion and 3 cases (4 %) with GTF2H2 deletion. The multiple real-time PCR was able to diagnose and predict the
prognosis of SMA patients. Simultaneously, the real-time PCR was applied to detect trace DNA from DBS and able
to make an early diagnosis of SMA.
Conclusion: The clinical and molecular characteristics of SMA in Southwest of China were presented. Our work
provides a novel way for detecting SMA in children by using real-time PCR and the potential usage in newborn
screening for early diagnosis of SMA.
Keywords: Spinal muscular atrophy, Multiplex real-time PCR, Newborn screening
Background
Spinal muscular atrophy (SMA) is one of the most com-
mon autosomal recessive disorders, with an incidence of
1 in 10,000 births [1]. The disease is characterized by the
degeneration of the anterior horn cells of the spinal
cord, resulting in symmetrical limb muscle atrophy and
weakness. SMA is classified into three clinical subtypes:
Type I SMA (Werdnig-Hoffmann disease, MIM253300),
Type II SMA (MIM253550) and Type III (Kugelberg-
Welander disease, MIM253400) [2]. The phenotypes of
these three subtypes of SMA are based on previous
reports [3].
Previously, a clinical diagnosis of SMA is confirmed by
muscle biopsy and electromyography (EMG). These pro-
cedures are time-consuming, affected by cross-talk and
post-processing artefacts and yield non-conclusive re-
sults in young infants [4, 5]. Thus, the diagnosis of SMA
is usually dependent on the doctor’s experience. When a
diagnosis is made, these infants often suffer from
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irreversible loss of neurological function. Early diagnosis
of SMA can improve outcomes, and the efficacy of early
diagnosis of SMA is also motivated by progress in thera-
peutic development [6].
Due to the shortcomings of the traditional diagnosis of
SMA, molecular diagnosis for SMA has gradually been
developed in recent years. For the molecular genetics of
SMA, all three clinical subtypes of SMA are associated
with mutations in the survival of motor neuron (SMN)
gene, which is mapped to chromosome 5q13. Normally,
this region contains one telomeric SMN1 gene (Genbank:
NG_008691.1) and one centromeric paralogue SMN2
gene (Genbank: NG_008728.1), which differs in exon 7 at
cDNA residue 840 (C for SMN1 and T for SMN2) [7, 8].
Patients with a homozygous deletion of SMN1 and a high
SMN2 copy number have a phenotype [8–10] due to the
small fraction of normal transcripts, which indicates that
infants with a homozygous mutation on c.840 of C > T
will have symptoms of SMA. Moreover, the phenotype is
correlated with the exon loss of several genes in the 5q13
region, such as apoptosis inhibitory protein (NAIP) (Gen-
bank: NG_008724.1) and general transcription factor IIH,
polypeptide 2 gene (GTF2H2) (Genbank: NT_187651.1)
[11]. The absence of exon 4 and 5 of NAIP may result
from an unequal crossing over, leading to severe SMA
[12]. The GTF2H2 gene and/or exon deletion might be
related to the severity of the disease, but its clinical signifi-
cance is still unclear [13].
The “gold standard” to detect a single nucleotide dif-
ference is DNA sequencing, and the best method to test
for the exon loss of several genes is multiplex ligation-
dependent probe amplification (MLPA) [11]. Only trace
DNA can be extracted from a dry blood spot (DBS),
which limits the application of DNA sequencing and
MLPA during newborn screening, when is the best time
to make an early diagnosis of SMA and treat in time,
based on DBS being the only specimen could be ob-
tained during newborn screening. Moreover, both of
these methods are time-consuming. For restriction frag-
ment length polymorphism (RFLP), which was estab-
lished by Van’s group [14], it is also time-consuming,
taking nearly 20 h to get the result, because the proced-
ure contains PCR and enzyme digestion; on the other
hand, it is hard to judge the results in daily work only by
22 base pairs differences through electrophoresis. Mul-
tiple real-time PCR has been used to detect single nu-
cleotide differences and exon loss in adults and newborn
screening [15, 16], which means multiple real-time PCR
diagnosing SMA is very likely to be successful. More-
over, the technique is high sensitivity, specificity and
rapid, so we chose it to establish a new method for SMA
diagnosis. We screened and chose the best multiple pairs
of primers and probes to establish the new real-time
PCR method, which was fast (<3 h), cheap (<US$2),
accurate, to analyse exons deletion of SMN, NAIP and
GTF2H2 genes.
In our study, the clinical and molecular characteristics
of a pediatric population with SMA from Southwest
China were presented. Real-time PCR was developed to
measure the gene mutation or deletion of key genes for
SMA and to further analyse genotype-phenotype correl-
ation; subsequently, 2000 cases of DBS were randomly




This retrospective and prospective study was performed
at the Children’s Hospital of Chongqing Medical University.
In this study, 1613 children with limb movement disorders
were screened, of which 141 children were confirmed to
exhibit the inclusion criteria listed in the “Interpretation”
section. These 141 children and an additional 100 normal
children were enrolled in a retrospective study, and their
blood specimens and medical records were collected. Sim-
ultaneously, 2000 DBS samples were randomly selected
from the Newborn Screening Center at the Children’s
Hospital of Chongqing Medical University to carry out the
prospective study. This study was approved by the Ethics
Committee of Children’s Hospital of Chongqing Medical
University, and the reference number was CHCMU-
20110005. Written informed consent was obtained from
the parents or legal guardians of the patients. The datasets
supporting the conclusions of this article are included
within the article and its additional files.
Interpretation
The inclusion criteria for the retrospective study were
patients confirmed with a normal nutritional status;
disorder on sitting, standing or walking; physical exam-
ination showing myasthenia or muscle atrophy; sequen-
cing, multiplex PCR and MLPA detected disorder; and
hospitalized. There was no inclusion criteria for the pro-
spective study because the samples were selected ran-
domly. The guidelines for SMA diagnosis and typing
were based on a previous report [3] and were described
in Additional file 1: Table S1.
Real-time PCR for SMN, NAIP and GTF2H2 genes in clinical
specimens
All 141 patients and 100 normal children were enrolled.
DNA was purified according to the manufacturer’s in-
structions (DP318-03, Tiangen Biotech, Beijing, China).
Next, 1 μl of DNA template (20 ng/μl) and 19 μl of a
real-time PCR master mix (FP203-02, Tiangen Biotech,
Beijing, China), as shown in Additional file 2: Table S2,
were used to perform real-time PCR. One sample should
be detected by two real-time PCR reactions: tube I and
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tube II. Tube I detected the mutation of SMN gene and
the deletion of NAIP exon5 and tube II detected internal
control and the deletion of NAIP exon4 and GTF2H2
exon 10.
The primers and probes used in this study are shown
in Additional file 3: Table S3 and were synthesized by
Invitrogen (Life Technologies Corporation, Shanghai,
China). Real-time PCR was performed on the Applied
Biosystem 7500 real-time PCR system (Applied Biosys-
tems, CA, USA) using the following conditions: 50 °C
for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C
for 15 s and 55 °C for 40 s. All standards and samples were
performed in triplicate.
Sequencing for SMN gene in clinical specimens
All 141 patients and 100 normal children were analysed
using Sanger DNA sequencing for the point mutation at
c.840 C > T of the SMN gene. The DNA template was
the same template used in real-time PCR. Each PCR
reaction was performed in a 50-μl volume, as shown in
Additional file 4: Table S4. PCR was performed on an
ABI-Verity Thermal Cycler (Applied Biosystems, Foster
City, California, USA) using the following conditions:
95 °C for 5 min, followed by 35 cycles of 95 °C for 30 s,
53 °C for 30 s and 72 °C for 30 s, and a final extension
step at 72 °C for 5 min. All samples were referred to
Sunny (Sunny Biotechnology Co. Ltd., Shanghai, China)
for sequencing.
Multiplex PCR and MLPA for NAIP and GTF2H2 genes in
clinical specimens
All 141 patients and 100 normal children were analysed
using multiplex PCR and MLPA for the NAIP and
GTF2H2 genes as previously reported [11, 17]. The DNA
template was the same template that was used in real-
time PCR. All of the conditions of each PCR reaction for
multiplex PCR were the same as those used for sequen-
cing. All of the samples were amplified in duplicate.
The PCR products of the NAIP and GTF2H2 genes
were used for DNA sequencing at Sunny (Sunny Biotech-
nology Co., Ltd., Shanghai, China) to confirm the expected
products. If there were exons missing, as determined by
electrophoresis, MLPA was performed on the DNA
samples to confirm the results at Genesky (Genesky Bio-
technologies Inc., Shanghai, China).
Real-time PCR for SMN, NAIP and GTF2H2 genes in DBS
Real-time PCR was performed on 2000 randomly se-
lected DBS samples. DNA was purified by Chelex-100
(1422842, Bio-Rad Laboratories Co., Ltd., Shanghai,
China). Briefly, one dried blood spot (diameter of 3 mm)
was clipped and mixed with 500 μl of nuclease-free
water to wash and was then centrifuged, and the super-
natants were discarded. Next, 5 % Chelex-100 was mixed
before the addition of 100 μl to each pellet, and the
mixture was incubated at 56 °C for 10 min. The mixture
was then mixed and centrifuged to harvest the
supernatants.
Real-time PCR was performed on the DNA templates of
the 6 μl and 14 μl PCR master mix, as shown in Additional
file 5: Table S5. All of the real-time PCR conditions were
the same as those described in the “Real-time PCR for
SMN, NAIP and GTF2H2 genes on clinical specimens”
section.
Statistics
The categorical data were expressed as percentages.
Differences in the clinical characteristics of the various
subtypes of SMA were determined using Fisher’s exact
test. The survival rates of the different groups were
analysed using log-rank. McNemar’s test was performed
to analyse the paired results of diverse methods, and p <
0.05 was considered statistically significant. Data were
Table 1 The general and clinical characteristics of children in
the retrospective study
General and clinical characteristics N (%)





< 6 m 60 (42.55)
7-18 m 45 (31.91)
> 18 m 36 (25.53)
Clinical characteristics
Congenital heart disease 11 (7.80)
Respiratory failure 14 (9.93)
Muscular atrophy 38 (26.95)
EMG abnormalities 117 (82.98)
Disorder on sitting/standing/walking 64 (45.39)/39 (27.66)/29 (20.57)
Prenatal
Ultrasonography abnormalities 3 (2.13)
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analysed using software SAS 9.13 (SAS Institute, Cary,
NC, USA).
Results
Patients and general characteristics
A total of 1613 children with limb movement disorders
were initially investigated, and 141 child patients sus-
pected to have SMA were enrolled in this study accord-
ing to the inclusion criteria. The age of the children with
limb movement disorders ranged from 1 month (m) to
15 years. The ratio of boys to girls was 1.660:1. The sub-
type of SMA was based on the onset age and clinical
phenotypes [3], and the children in the study were di-
vided into groups of ≤6 m, 6–18 m and ≥18 m. The gen-
eral and clinical characteristics of the SMA-suspected
children enrolled in the study are listed in Table 1.
There were 75 SMA children based on the SMA
diagnosis guideline [3], and most of these children were
grouped as Type I and Type II (Table 2). From this table,
children with Type I SMA were more susceptible to con-
genital heart disease and respiratory failure and more
prone to decreased fetal movement compared to children
with Type II SMA. However, there were no significant dif-
ferences between the two groups (Table 2). The remaining
66 children had Duchenne or Becker muscular dystrophy
(DMD/BMD), mitochondrial encephalomyopathy (ME)
and Charcot-Marie-Tooth (CMT) (Table 1).
Molecular diagnosis and prognosis of SMA using novel
real-time PCR methods
There were no significant differences of abnormal
physical examination syndromes and laboratory detec-
tion between SMA and other neurological disorders,
for instance, DMD/BMD [18]. The basic molecular
diagnosis for SMA was performed by detecting the
presence of a homozygous exon 7 deletion in the
SMN gene, as previously reported [8, 9]. Deletions in
the NAIP and GTF2H2 genes were correlated with
the severity and phenotype of SMA [12, 13], which
contributed to SMA prognosis and typing. These real-
time PCR results demonstrated a typical “S-shape”
curve in different colors, and the threshold of relative
fluorescent units (RFU) was set as 102. The meaning
of the colorful curves were shown in Fig. 1, and the
real-time PCR results are shown in Fig. 1, indicating
that this new real-time PCR was able to detect the
exons with a homozygous loss of SMN, NAIP and
GTF2H2.
There were 71 (94.67 %) SMA patients with homozy-
gous deletion on SMN1 among 75 SMA patients; 6
SMA patients with a homozygous deletion of NAIP
(exon 4 and exon 5), 3 SMA patients with a homozygous
deletion of NAIP (exon 4) and 3 SMA patients with a
homozygous deletion of GTF2H2 (exon 10). Eleven of
the patients were diagnosed as having Type I SMA, and











Boy 24 (58.54) 19 (65.52) 3 (60) 46 (61.33)
Girl 17 (41.46) 10 (34.48) 2 (40) 29 (38.67)
Clinical symptoms*
Congenital heart disease 3 (7.32) 0 0 3 (4) 0.5137
Respiratory failure 6 (14.63) 2 (6.90) 0 8 (10.67) 0.7308
Muscular atrophy 20 (48.78) 13 (44.83) 2 (40) 35 (46.67) 0.9835
EMG abnormalities 39 (95.12) 28 (96.55) 4 (80) 71 (94.67) 0.4405
Prenatal*
Ultrasonography abnormalities 0 0 0 0 -
Decreased fetal movement 3 (7.32) 2 (6.90) 0 5 (6.67) 1.0000
CK value*
Normal 6 (14.63) 8 (27.59) 2 (40) 16 (21.33) 0.3391
Elevation 35 (85.37) 21 (72.41) 3 (60) 59 (78.67)
Molecular detection
Homozygous mutation at c.840 C > T in SMN gene 40 (97.56) 26 (89.66) 5 (100) 71 (94.67)
Deletion of NAIP exon4 and 5 6 (14.63) 0 0 6 (8)
Deletion of NAIP exon4 3 (7.32) 0 0 3 (4)
Deletion of GTF2H2 exon10 2 (4.88) 1 (3.45) 0 3 (4)
*Fisher’s exact test
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the remaining patients were diagnosed as having Type II
SMA (Table 2). The percentage of the NAIP and GTF2H2
homozygous deletions were only 12 % (9/75) and 4 % (3/
75), respectively, among all of the SMA children (Table 2).
Consistency of SMN, NAIP and GTF2H2 gene detection
among Sanger DNA sequencing, MLPA and real-time PCR
The “gold standard” for detecting a single nucleotide
difference and exon loss of several genes [11, 17] is
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Fig. 1 The amplification curves of real-time PCR. The threshold of RFU was set to be 102. The red curve represented NAIP exon5; the black curve
represented wild type of SMN gene; the blue curve represented mutation type of SMN; the yellow curve represented GTF2H2 exon10, the purple
curve represented NAIP exon4 and the green curve represented internal control. a The image represented that the patient was only with heterozygous
mutation of SMN and no mutation on NAIP exon5; (b) The image represented that the patient was with homozygous mutation of SMN and no
mutation on NAIP exon5; (c) The image represented that the patient was normal for SMN and NAIP exon5; (d) The image represented that the patient
was with homozygous mutation of SMN and the deletion of NAIP exon5; (e) The image represented that there was no mutation on GTF2H2 exon10
and NAIP exon4, and internal control was normal; (f) The image represented that the patient was with the deletion of NAIP exon4; (g) The image
represented that the patient was with the deletion of GTF2H2 exon10; (h) The image represented that there was no amplification for internal control,
and sample should be detected again
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DNA sequencing and MLPA, which were simultaneously
used to confirm the results of our newly designed real-
time PCR. Wild-type SMN and the homozygous mutation
at c.840 C > T in the SMN gene were confirmed using
Sanger DNA sequencing (Fig. 2a, b). The electrophoresis
results of this new multiplex real-time PCR, including
normal samples, samples with homozygous mutations
in NAIP in exon 4, homozygous deletions of NAIP in
exon4 and exon5 and homozygous deletions of
GTF2H2 in exon 10, were shown in Fig. 2c. The
wild-type and patients with the deletion of NAIP
(exon4 or 5) or GTF2H2 (exon10) detected by single
PCR were shown in Fig. 2d.
If there was no exon deletion in SMN, NAIP and
GTF2H2, then all of the PCR products were confirmed
using DNA Sanger sequencing (Fig. 2e, f and g). If any
exon homozygous deletions were detected, then the
abnormal and normal samples were confirmed using
MLPA. There were four main peaks for normal samples,
which indicated no deletion of the three exons of NAIP
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Fig. 2 Detection SMN, NAIP and GTF2H2 genes by multiplex PCR and DNA Sanger sequencing. a The DNA sequence result of wild-type at c.840
of SMN (exon7); (b) The DNA sequence result of homozygous mutation of C > T at c.840 of SMN (exon7); (c) The multiplex PCR image for NAIP
and GTF2H2 gene deletions. M, Marker; a, NAIP exon4; b, GTF2H2 exon10; c, NAIP exon5; (d): The single PCR image for wild type and NAIP or
GTF2H2 gene deletions. M, Marker; 1, 3, 5, samples of wild type of NAIP and GTF2H2; 2, patients with NAIP exon5 deletion; 4, patients with NAIP
exon4 deletion; 6, patients with GTF2H2 exon10 deletion; (e) The DNA sequence map of NAIP exon4; (f) The DNA sequence map of NAIP exon5;
(g) The DNA sequence map of GTF2H2 exon10
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(exon 4 and exon 5) and GTF2H2 (exon 10) (Fig. 3a).
For the three different types of homozygous deletions of
the NAIP or GTF2H2 gene, one or more peaks were
observed to be missing (Fig. 3b, c and d).
The results of this novel real-time PCR were compared
with those obtained from DNA Sanger sequencing and
multiplex PCR plus MLPA (Table 3). The accuracy of
real-time PCR for the homozygous exon 7 deletion in
the SMN gene was 99.6 % (240/241), and the false posi-
tive and negative rates of real-time PCR were 0 and
0.6 % (1/171), respectively, based on the results of DNA
Sanger sequencing, indicating that this new real-time
PCR was an ideal sequencing alternative for the detection
of the SMN point mutation (Table 3). Simultaneously, the
heterozygous SMN exon 7 deletion was found in no SMA
patients, but was found in 62 children among the DMD/
BMD, ME and normal patients, as confirmed using DNA
Sanger sequencing (Table 4).
Interestingly, the accuracy of real-time PCR for NAIP
exon 4 and exon 5 was 98.8 % (238/241) and 99.2 %
(239/241), respectively. The false positive rates of this
new real-time PCR for NAIP exon 4 and 5 were 1.3 %
(3/232) and 0.9 % (2/235), respectively, and the false
negative rates of this new PCR for NAIP exon 4 and 5
were both 0. The accuracy of this novel real-time PCR
for GTF2H2 exon 10 was 99.2 % (239/241), and the false
positive and negative rates were 0.8 % (2/238) and 0, re-


































Fig. 3 MLPA detection for NAIP and GTF2H2 genes. a The representative MLPA figures of normal sample; (b) The representative MLPA figures of
NAIP exon4 deletion; (c) The representative MLPA figures of deletion of NAIP exon4 and 5; (d) The representative MLPA figures of GTF2H2 exon10
deletion. a: Internal control; b: Exon4 of NAIP; c: Exon5 of NAIP; d: Exon10 of GTF2H2
Table 3 The correlation of SMN, NAIP and GTF2H2 in different methods
MLPA +multiplex PCR/Real-time PCR (%) Sequencing/Real-time PCR (%) χ2 P value*
+/+a −/+ b +/− c −/− d +/+ e −/+ f +/− g −/− h
NAIP (exon4) 9 (3.7) 3 (1.2) 0 229 (95.1) 3.0 0.0833
NAIP (exon5) 6 (2.5) 2 (0.8) 0 233 (96.7) 2.0 0.1573
GTF2H2 (exon10) 3 (1.2) 2 (0.8) 0 236 (98.8) 2.0 0.1573
SMN 70 (29.1) 0 1 (0.4) 170 (70.5) 1.0 0.3173
aThere were exons deletion of NAIP or GTF2H2 detected for both methods, meaning true positive for real-time PCR compared with MLPA +multiplex PCR
bThere was no exon deletion of NAIP or GTF2H2 detected by MLPA +multiplex PCR but an exon deletion detected by real-time PCR, meaning false positive for
real-time PCR compared with MLPA +multiplex PCR
cThere was exon deletion of NAIP or GTF2H2 detected by MLPA +multiplex PCR but not detected by real-time PCR, meaning false negative for real-time PCR
compared with MLPA +multiplex PCR
dThere was no exon deletion for both MLPA +multiplex PCR and real-time PCR, meaning true negative for real-time PCR compared with MLPA +multiplex PCR
eThere was homozygous mutation on SMN c.840 C > T for both methods, meaning true positive for real-time PCR compared with DNA sequencing
fThere was no homozygous mutation on SMN c.840 C > T detected by Sanger DNA sequencing but detected by real-time PCR, meaning false positive for real-time
PCR compared with DNA sequencing
gThere was homozygous mutation on SMN c.840 C > T for Sanger DNA sequencing but not detected by real-time PCR, meaning false negative for real-time PCR
compared with DNA sequencing
hThere were normal and heterozygous mutation on SMN c.840 C > T for both Sanger DNA sequencing and real-time PCR, meaning true negative for real-time PCR
compared with DNA sequencing
*McNemar test
Liu et al. BMC Neurology  (2016) 16:141 Page 7 of 12
PCR in groups of SMA children and normal children.
These results revealed that this new real-time PCR was
an ideal substitution of MLPA for NAIP and GTF2H2
mutation detection (Table 3). In addition, heterozygous
deletions of NAIP or GTF2H2 were found in 16 children,
but no deletions were found in SMA patients using
MLPA (Table 4).
Prognosis of Type I SMA patients via the detection of
SMN, NAIP and GTF2H2 genes
The prognosis of patients is helpful to guide clinical
treatment. Survival rate analysis was performed to
evaluate the prognosis of patients with or without a
homozygous gene deletion. There was only 1 patient
with a homozygous deletion in GTF2H2 diagnosed
with Type II SMA, and thus, only the survival rate of
Type I SMA patients was analysed. Among the 11
Type I SMA children, there was no patient with a
complex gene deletion of NAIP or GTF2H2. The sur-
vival rates between Type I SMA patients with a
homozygous deletion of NAIP or GTF2H2 and pa-
tients without a deletion in NAIP or GTF2H2 were
analysed (Fig. 4a). There was a much lower survival
rate in patients with a homozygous deletion in NAIP
or GTF2H2 (p < 0.01), particularly in the first 2 months
after suffering from pneumonia (Fig. 4a).
Due to the different types of gene deletions, we deter-
mined if there was a difference in the prognosis among
patients with a homozygous deletion in one exon, two
exons, or no exons in SMA children. Type I SMA patients
were divided into three groups: patients without a deletion
in NAIP or GTF2H2, patients with a homozygous deletion
in one exon of NAIP or GTF2H2, and patients with a
homozygous deletion in exon 4 and 5 of NAIP (Fig. 4b).
There was a much lower survival rate of patients with a
homozygous deletion in one or two exons compared with
patients without a deletion (p < 0.05), but there was no
significant difference between patients with a homozygous
deletion in one exon and those with a homozygous dele-
tion in exon 4 and 5 of NAIP in Type I SMA patients.
According to He’s report [11], the copy number of
SMN2 was related to prognosis. In our study the copy
number of SMN2 varied from 2–4 of our SMA patients,
Table 4 Heterozygous mutations of SMN, NAIP and GTF2H2
genes among children
SMN NAIP GTF2H2
Exon7 Exon4 Exon5 Exon10
SMA 0 0 0 0
DMD/BMD 38 1 1 0
ME 1 0 0 0
CMT 0 0 0 0
Normal 23 7 3 4
Fig. 4 The survival analysis of type I SMA patients. a There were two groups of
SMA type I patients: (1) patients with NAIP or GTF2H2 deletion, shown as red
curve, n=11; (2) patients without NAIP or GTF2H2 deletion, shown as green
curve, n=30. (b) SMA type I patients were classified into three groups: (1)
patients with exon4 and 5 of NAIP deletion, shown as red curve, n=6; (2)
patients with one exon deletion in NAIP or GTF2H2, shown as green curve, n=
5; (3) patients without NAIP or GTF2H2 deletion, shown as blue curve, n=30. (c)
SMA type I patients were classified into three groups: (1) patients’ copy number
(CN) of SMN2=2, shown as blue curve, n=19; (2) patients’ copy number (CN)
of SMN2=3, shown as red curve, n=16; (3) patients’ copy number (CN) of
SMN2=4, shown as green curve, n=6. (d) SMA type II patients were classified
into three groups: (1) patients’ copy number (CN) of SMN2=2, shown as blue
curve, n=8; (2) patients’ copy number (CN) of SMN2=3, shown as red curve, n
=11; (3) patients’ copy number (CN) of SMN2=4, shown as green curve, n=10
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as shown in Table 5. The relationship between the copy
number of SMN2 and patients’ prognosis was analysed,
as shown in Fig. 4c, d. There were no significant differ-
ences among patients with different copy number of
SMN2 in Type I and Type II SMA patients (p > 0.05) in
our study. All the patients with Type III SMA were still
alive.
Novel real-time PCR for trace DNA
Although real-time PCR can replace DNA Sanger se-
quencing and MLPA for detecting mutations of SMN,
NAIP and GTF2H2, it is necessary to determine whether
it can function in newborn screening with trace DNA
samples. We randomly selected 2000 DBS samples from
2011 to 2014 using the new real-time PCR method for
the detection gene mutations (Table 6).
All trace DNA samples were successfully collected and
purified from the 2000 DBS samples. There were 23
samples detected as positive in the first run and all of
them were reconfirmed by our Real-time PCR and then
DNA sequenced. Twenty-two of them were proven to
be false-positive, so there was only one sample, whose
ID number was NS-13050012. This patient was first hos-
pitalized due to pneumonia and myasthenia when he
was 1 month old in May 2013, who was homozygous for
the SMN exon 7 deletion, and the remaining 1999 sam-
ples were negative for SMN, NAIP and GTF2H2 dele-
tion. For the negative samples, 1997 of the patients had
no symptoms related to SMA and 2 of the patients had
limb movement disorders after a follow-up investigation.
The 2 children that had limb movement disorders were
subsequently diagnosed with progressive muscular
dystrophy.
On the other hand, we collected peripheral blood from
new SMA patients to make DBS from January 1st to
May 16th. There were 36 SMA patients. The results were
shown in Table 7. It was obvious that the ability to de-
tect DNA from DBS of our novel real-time PCR was the
same as detecting DNA from peripheral blood. The low
positive rate of the method in newborn screening DBS
was related to the samples, which only contained 1 SMA
patient, not because of the limit of our real-time PCR.
Discussion
Here, we established a novel real-time PCR method for
detecting mutations in the SMN, NAIP and GTF2H2
genes. The accuracy of this real-time PCR method for
detecting the presence of a SMN point mutation or a
homozygous deletion in NAIP, GTF2H2 exons was at
least 98.8 % compared with DNA Sanger sequencing
and MLPA. Real-time PCR is a fast and an ideal method
to replace DNA Sanger sequencing, multiplex PCR, and
MLPA for the diagnosis of SMA and requires small
amounts of DNA [19]. Real-time PCR is also suitable for
application in newborn screening for SMA, similar to
Somech’s report of T cell receptor excision circles in
combined T and B cell immunodeficiency [20]. However,
real-time PCR was not able to distinguish between dif-
ferent sub-types of SMA patients. This may be due to
the correlation between the genotypes and phenotypes
of SMA with hundreds of genes that are not located on
chromosome 5q [21, 22], and thus, whole genome se-
quencing should be further explored.
The incidence of SMA was 4.65 % (75/1613) in chil-
dren with limb movement disorders in the southwest
part of China. Interestingly, most of our SMA patients
were classified as Type I and II (Table 1). Type I SMA
children were more susceptible to congenital heart dis-
eases and respiratory failure and were more prone to de-
creased fetal movement compared with Type II SMA
children, consistent with previous reports [23–25]. Nei-
ther the proportion of muscular atrophy abnormalities
nor EMG were found in different subtypes of SMA
patients.
In our SMA children, 94.67 % (71/75) displayed a
homozygous SMN1 exon 7 deletion, which was similar
to the findings obtained in a previous report [26]. How-
ever, the odds ratios of NAIP and GTF2H2 homozygous
deletions were only 12 % and 4 %, respectively, among
SMA patients, which was much lower than the report in
east China [11], indicating the different inheritance char-
acteristics for SMA in southwest China. In our study,
there was no heterozygous mutations or deletions of
Table 5 SMN2 copy number in different sub-types of SMA
SMA
sub-types
SMN2 copy number Total
2 3 4
Type I 19 (46.34) 16 (39.02) 6 (14.63) 41
Type II 8 (27.59) 11 (37.93) 10 (34.48) 29
Type III 1 (20) 2 (40) 2 (40) 5
Total 28 (37.33) 29 (38.67) 18 (24) 75
Table 6 Real-time PCR for Newborn screening
2011 2012 2013 2014 (up to July)
DBS screened/
Total
213/33499 637/99841 706/110592 444/69224
Positive number 0 0 1 0
Table 7 Detection of SMA through DNA from peripheral blood
or from DBS
SMN deletion NAIP deletion GTF2H2 deletion
Exon7 Exon4 Exon5 Exon10
Peripheral blood
(n = 36)
35 4 1 0
DBS (n = 36) 35 4 1 0
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SMN, NAIP and GTF2H2 found in SMA patients. In-
deed, the multiplex real-time PCR detected a SMN het-
erozygous exon 7 deletion, as shown in Fig. 1a. In
addition, real-time PCR detected heterozygous deletions
of the NAIP or GTF2H2 gene when a normal sample
with no deletion of the genes was used as an internal
control and an equal amount of DNA from patient was
amplified (data not shown). Not only patients with
DMD/BMD or ME and normal children, as shown in
Table 4, but also 20 pairs of the parents of SMA patients
(data not shown), who had no symptom, were found to
have heterozygous mutations of SMN1, NAIP and
GTF2H2. Some of them had no clinical symptom and
some of them had clinical symptoms not related to mu-
tations of SMN1, NAIP and GTF2H2. There was no clin-
ical significance for heterozygous mutations of SMN1,
NAIP and GTF2H2.
Among the Type I SMA patients, the development of
SMA was much faster in patients with a homozygous
deletion in NAIP or GTF2H2 compared to patients with-
out this type of deletion. For the 11 Type I SMA pa-
tients, 3 patients demonstrated decreased fetal
movement during pregnancy. Among these 3 patients,
the patient with a homozygous deletion in exon 4 of
NAIP had a poor prognosis (the child died within the
first 2 months). The amount of samples was too small to
obtain a conclusion that decreased fetal movement may
signal a bad prognosis for SMA patients. Thus, more
cases of SMA children should be further investigated.
The relationship between the prognosis of patients
and SMN2 copy number in our study was different from
others [11, 27]. There were no significant differences be-
tween the possibility of developing to different sub-types
of SMA and SMN2 copy numbers in our study accord-
ing to Table 5, whereas an inverse relationship between
SMN2 copy number and possibility of developing to
Type I SMA in He J’s research. Maybe different genetic
background result in this different prognosis comparing
with He J’s research. The onset age of most of our type I
SMA patients (38/41, 92.7 %) was <2 months and 72.4 %
(21/29) of type II SMA patients carried more than 3
copies of SMN2, whereas the onset age of Qu’s type I pa-
tients was 31.1 % (33/106) and copies of SMN2 of Qu’s
type II patients was 96 %. As Qu’s research, the clinical
and genetic characters of our patients were more severe,
leading to worse survival rate.
Only one DBS-positive sample, whose ID number was
NS-13050012, was analysed in our study. The doctor di-
agnosed that the baby suffered from Type I SMA using
DNA sequencing and MLPA. The child was nursed as a
Type I SMA patient and was still alive until September
2014, with no obvious symptoms except non-sitting. If
we performed the newborn screening for SMA for new-
born babies, children with SMA will benefit from being
diagnosed as Type I SMA at an early age and can begin
an early specific nursing program. Thus, their prognosis
will improved, similar to the child in our study.
There are four main methods to detect SMA: Sanger
DNA sequencing, MLPA, RFLP and multiple routine
PCR. No one was used in newborn screening. Sanger
DNA sequencing and MLPA are both time consuming
(>2 weeks), expensive (>US$21) and high amount of
DNA required (amount of DNA is trace in newborn
screening); RFLP is also time consuming (20 h) and not
able to detect exons deletion of NAIP and GTF2H2;
multiplex routine PCR is not able to detect exon 7 dele-
tion of SMN1 and it is more subjective because of being
judged by electrophoresis gel image; even the method of
RFLP with multiplex routine PCR is also time consum-
ing and subjective to judge results. Our new approach is
fast (<3 h), cheap (<US$2), objective and able to analyse
exons deletion of SMN, NAIP and GTF2H2 genes simul-
taneously with trace DNA.
According to Prior’s and Stabley’s studies [28, 29],
there are several limitations of real-time PCR. At the
same time, digital PCR (dPCR) is able to detect SMN
mutation. Moreover, for the coefficients of variation,
dPCR is even better than real-time PCR.
For limitations of real-time PCR, (1) we recommended
eathylene diamine tetraacetic acid (EDTA) as anticoagu-
lant for periphery blood sample, avoiding heparin for its
inhibiting Taq polymerase activity. Our method detected
more than 200 EDTA peripheral blood and 2000 DBS
samples, and the amplification efficiency was excellent,
so the compounds in specimen did not shown inhib-
ition; (2) it is possible that DNA sequence variants lo-
cated under the primer binding sites may be a problem
to influence the results. To avoid the question, we need
to add another pair of primers to cover outside of bind-
ing sites of the primers we used to amplify samples in
future; (3) for data analysis, repeating reactions twice
and evaluating the capability of equipment could ensure
the quality of results to a certain extent.
The recent new method of dPCR is suitable and prom-
ising for detecting SMN mutation. However, the ability
of dPCR to simultaneously detect NAIP and GTF2H2
mutation and for DBS is not available and need further
evaluation. Moreover, dPCR is more expensive (>US$15)
in China and specific equipment is required. In a word,
the Real-time PCR for SMN, NAIP and GTF2H2 is
cheaper and feasibility for clinical usage at present in
China.
Conclusions
In summary, we have provided a better understanding of
the incidence, clinical and laboratory characteristics of
SMA in southwest China and established a new fast,
cheap and accurate real-time PCR method for detecting
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SMA during newborn screening, which will be helpful in
maintaining the motor function of Type I and II SMA
patients in the near future (ClinicalTrial.gov. Safety and
efficacy of olesoxime (TRO19622) in 3–25 years SMA pa-
tients. From http://clinicaltrials.gov/show/NCT01302600.
Accessed October 8, 2013). Combined with SMA therapy
development, SMA patients may also be specifically
treated in a more timely fashion in the future [6]. Further-
more, whole genome sequencing should be explored to
determine the genotype-phenotype correlation and typing
of SMA.
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